Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.

Abstract excerpt

OBJECTIVE: Despite the clinical efficacy of tumor necrosis factor inhibitors (TNFi), the manner in which TNF-α contributes to disease in patients with ankylosing spondylitis (AS) remains unresolved. We investigated the relationship between TNF-α gene promoter region polymorphism, serum TNF-α levels, and clinical phenotype. METHODS: We did a cross-sectional and longitudinal cohort study in TNFi-naive patients with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antirheumatic Agents
• Share to Blood Sedimentation